Mirador Accelerates Multi-Asset Clinical Pipeline in Immuno-Fibrotic Disease; Closes $250 Million Series B with Premier Investors
Advancing multiple programs across Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis; 10+ clinical readouts expected by year-end 2027 Closed $250 million Series B financing in Q3 2025, adding new investors T. Rowe…